


| CERTIFICATE OF MAILING | | | |
|---|---|--|-------------------|
| I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date. | | | |
| Typed or Printed Name | Steven F. Goldstein | | |
| Signature |  | | Date |
| | | March 21, 2003 | |
| INFORMATION DISCLOSURE STATEMENT Address to: Commissioner for Patents Washington, D.C. 20231 | | Attorney Docket | IRVN-007CON2 |
| | | First Named Inventor | GATANAGA, TETSUYA |
| | | Application Number | 09/752,639 |
| | | Filing Date | December 29, 2000 |
| | | Group Art Unit | 1646 |
| | | Examiner Name | MURPHY, JOSEPH F. |
| | | Title: "SCREENING FOR DRUGS THAT AFFECT TNF RELEASING ENZYME" | |

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. This is being filed *after* three months of the filing date of this national application or the date of entry of the national stage as set forth in §1.491 in an international application or *after* the mailing date of the first Office Action on the merits, whichever event occurred last, but *before* the mailing date of either a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.

A Form PTO-SB/08A listing the references accompanies this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

- ☒ All of the references identified herein are being submitted prior to the final determination on patentability by the Office.
- ☐ All of the references identified herein were cited in an International (PCT) Search Report dated *, in a PCT application corresponding to the above-identified U.S. application. A copy of the Search Report, including an indication of the purported relevance of the cited documents, is enclosed herewith. Copies of the references are submitted herewith.
- ☐ All of the references identified herein were disclosed in parent application Serial No. 09/712,813 and, as such, copies thereof are not included pursuant to the provisions of 37 C.F.R. §1.98(d), except if noted below.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. §102.

Att'y Dkt. No.: IRVN-007CON2
USSN: 09/752,639

X Please charge the \$180.00 fee required by 37 C.F.R. §1.97(c) and set forth in 37 C.F.R. 1.17(p) and any additional fees which may be required by this paper or any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21, or to credit any overpayment, to Deposit Account No. 50-0815, order number IRVN-007CON2.

Date: March 21, 2003

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

By: Carol L. Francis
Carol L. Francis
Registration No. 30,513